Abstract
Clinical trials with daptomycin were halted in December 1990 because of treatment failures including two resistant Staphylococcus aureus strains. High protein binding of daptomycin (> 90%) and the lower-than-expected concentrations in serum with the dosage regimen of 3 mg/kg of body weight every 12 h may have contributed to these failures. To evaluate the effect that higher concentrations would have on bactericidal activity measured by time-kill curves, peak and trough concentrations were estimated for dosage regimens of 3, 5, and 10 mg/kg every 12 h. MICs, MBCs, and killing curves for daptomycin and vancomycin were performed by using the estimated concentrations with four S. aureus strains obtained from patients who failed daptomycin therapy for endocarditis. MICs and MBCs of daptomycin demonstrated a greater inoculum effect than those of vancomycin; MICs and MBCs of daptomycin increased three- to fourfold, but those of vancomycin increased only one- to twofold when the inoculum was increased from 5 x 10(5) to 5 x 10(7) CFU/ml. No pH-dependent effect on MICs or MBCs was seen. Strenuous experimental conditions were chosen: high inoculums (5 x 10(7) CFU/ml), extremes of pH (6.4, 7.4, and 8), and stationary and exponentially growing organisms; and all experiments completed in the presence of pooled human serum. Daptomycin exhibited concentration-dependent killing and statistically faster kill rates than vancomycin against stationary- or exponential-growth-phase organisms. A pH-dependent decrease in activity with daptomycin was also demonstrated. Daptomycin and vancomycin produced higher kill rates against exponentially growing organisms. A pH-dependent decrease in activity with daptomycin was also demonstrated. Daptomycin and vancomycin produced higher kill rates against exponentially growing organisms. The results indicate that the use of higher dosage regimens with compounds similar to daptomycin may be capable of overcoming the effects of pH, high inoculum, and protein binding.
MeSH Terms
Blood Bactericidal Activity/drug effects
Culture Media
Daptomycin
Humans
Hydrogen-Ion Concentration
Microbial Sensitivity Tests
Peptides/blood,pharmacology
Protein Binding/drug effects
Serum Bactericidal Test
Staphylococcus aureus/drug effects,growth & development
Vancomycin/blood,pharmacology
Chemicals
Culture Media
Peptides
Vancomycin
Daptomycin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Lamp K C
College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, Michigan.
Rybak M J
Bailey E M
Kaatz G W
References (23)
23 references, click to expand
-
Inhibition of membrane potential-dependent amino acid transport by daptomycin.
Antimicrob Agents Chemother. 1991 Dec;35(12):2639-42
PMID: 1687346
-
Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.
J Infect Dis. 1977 Aug;136(2):196-204
PMID: 408424
-
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 1990 Nov;34(11):2081-5
PMID: 1963526
-
Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.
Antimicrob Agents Chemother. 1989 Apr;33(4):585-8
PMID: 2543286
-
In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria.
Antimicrob Agents Chemother. 1989 Aug;33(8):1383-4
PMID: 2552910
-
MLTIDOSE: a multiple-dose simulation program for linear systems characterized by exponential functions.
Drug Metab Rev. 1989-1990;21(3):463-9
PMID: 2640444
-
Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.
Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9
PMID: 2821889
-
Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus.
Antimicrob Agents Chemother. 1988 Apr;32(4):454-7
PMID: 2837137
-
Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
Antimicrob Agents Chemother. 1987 Apr;31(4):625-9
PMID: 3038001
-
Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria.
Antimicrob Agents Chemother. 1991 Sep;35(9):1824-8
PMID: 1952852
-
LY146032: activity and resistance development in vitro.
J Antimicrob Chemother. 1987 Oct;20(4):513-7
PMID: 2824427
-
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
Antimicrob Agents Chemother. 1986 Oct;30(4):532-5
PMID: 3024560
-
Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.
Antimicrob Agents Chemother. 1991 Sep;35(9):1710-6
PMID: 1659305
-
Daptomycin disrupts membrane potential in growing Staphylococcus aureus.
Antimicrob Agents Chemother. 1991 Nov;35(11):2282-7
PMID: 1666494
-
Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.
Antimicrob Agents Chemother. 1991 Jun;35(6):1089-92
PMID: 1834010
-
Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.
Antimicrob Agents Chemother. 1991 Jul;35(7):1413-22
PMID: 1929302
-
Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 1990 Oct;34(10):1925-31
PMID: 1963288
-
Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination.
Antimicrob Agents Chemother. 1990 Dec;34(12):2348-53
PMID: 1965105
-
Effect of human serum on the bactericidal activity of daptomycin and vancomycin against staphylococcal and enterococcal isolates as determined by time-kill kinetic studies.
Diagn Microbiol Infect Dis. 1990 May-Jun;13(3):245-52
PMID: 2166634
-
Comparison of in vitro activity of daptomycin, vancomycin and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics.
Chemotherapy. 1989;35(3):168-73
PMID: 2548817
-
Suboptimal effect of daptomycin in the treatment of bacteremias.
South Med J. 1989 Nov;82(11):1414-5
PMID: 2554510
-
Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.
Antimicrob Agents Chemother. 1987 Aug;31(8):1210-5
PMID: 2820300
-
Bactericidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies.
Antimicrob Agents Chemother. 1987 Jul;31(7):1014-6
PMID: 2821883